After studying the key metrics of the Grosvenor Gold Project ( page 3 of the RNI Quarterly Report dated 30 January, 2015 ) and yesterdays RNI announcement, it would appear that RNI on its own is having some difficulty in obtaining sufficient financie confidence for project financing despite the much improved AUD price of gold.
Total debt required is $ 40 including a $ 2 mil contingency amount required pre-production... Then comes the cash flow !
IF RNI had a jv partner then of course a financier would likely feel much more comfortable. ( more on this in a little while ! )
Base Case from the metrics suggests debt payback in just 2.25 years and free cash flow of $ 92 million over 4.75 years
IF someone such as MZM became a 50% jv partner then part of that deal would be MZM financing 50% of the $ 40 million debt required, which basis its balance sheet/chinese connections it could easily do, resulting in MZM having its desired "near term "production and cash flow available in say 9 months time.
Succh a scenario would be a massive boost to the value of MZM.
- Forums
- ASX - By Stock
- E25
- Grosvenor Gold Project
Grosvenor Gold Project
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add E25 (ASX) to my watchlist
|
|||||
Last
23.5¢ |
Change
0.035(17.5%) |
Mkt cap ! $51.67M |
Open | High | Low | Value | Volume |
21.0¢ | 24.0¢ | 21.0¢ | $112.7K | 488.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 60014 | 23.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.5¢ | 65863 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 60014 | 0.235 |
1 | 39387 | 0.215 |
5 | 273670 | 0.210 |
1 | 10000 | 0.205 |
11 | 495004 | 0.200 |
Price($) | Vol. | No. |
---|---|---|
0.245 | 65863 | 2 |
0.250 | 21957 | 3 |
0.255 | 19607 | 1 |
0.265 | 1010 | 1 |
0.270 | 20000 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
E25 (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online